Papadavid E, Kapniari E, Pappa V, et al. - In the present study, the researchers tested the safety and effectiveness of brentuximab vedotin (BV) in mycosis fungoides (MF)/Sezary syndrome (SS) patients with variable CD30 positivity in the real-life cohort and explore potential predictors. The study included information from 72 MF/SS patients from 9 EORTC (European Organization for Research and Treatment of Cancer) centers. Participants in the study were 72 patients. BV is an effective treatment option for MF/SS patients, including those with variable CD30 positivity, LCT, SS, longer disease duration, and who have been previously treated.